Preparing for Kidney Precision Medicine Clinical Trials Workshop
To gain a better understanding of the kidney patient therapeutic journey and to define candidate indicators for precision medicine pathway, target and trial readiness. This workshop will identify kidney precision medicine clinical trial barrier and potential solutions and to identify concepts relative to advancing precision medicine clinical trials not yet considered.
- Bring in the patient's voice to advance treatments for kidney disease.
- Define candidate indicators for precision medicine pathways, targets, and trial readiness.
- Identify kidney precision medicine clinical trial barriers and potential solutions.
- Identify concepts relative to advancing precision medicine clinical trials not yet considered.
Progressive kidney disease affects how individuals feel, function, and survive. Therapies for individuals with kidney disease have only modest efficacy; both risk for severe toxicity and selection of treatments are not well informed by precise assessment of disease mechanism(s) active at the time of decision-making. In this standard of care context, many people with chronic kidney disease experience a series of therapies with limited efficacy and, ultimately, progress to kidney failure. Scientific advances are increasing awareness and improving the ability to assess molecular mechanisms of kidney disease and elucidation of associated therapeutic targets.
|Harvard University; Brigham and Women’s Hospital
|Glenn M. Chertow
|Paul T. Conway
|American Association of Kidney Patients
|University of Michigan
|Kidney Health Initiative
|University of California-San Francisco
|U.S. Food and Drug Administration
|Debbie Gipson, Kevin Abbott, Kevin Chan, Raquel Greer, Paul Kimmel, Susan Mendley, Afshin Parsa, Tracy Rankin, Cindy Roy, Ivonne Schulman
March 17, 2024
Natcher Conference Center
NIH Main Campus
This is a hybrid workshop. Virtual participation is available. For those attending via webinar, the link will be distributed via email prior to the date of the event.
Debbie Gipson, M.D., M.S.
The Scientific Consulting Group, Inc.